Hatch-Waxman Patent Litigation Strategies

July 2020

This practice note discusses strategies that counsel for brand-name and generic drug companies may employ in pharmaceutical patent litigation under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act. It focuses on litigating infringement and validity of active pharmaceutical ingredient (API), formulation, and treatment patents using court decisions as a guide to what works and what doesn’t for each side in Hatch-Waxman litigation.

This excerpt from Lexis Practice Advisor®, a comprehensive practical guidance resource providing insight from leading practitioners, is reproduced with the permission of LexisNexis. Reproduction of this material, in any form, is specifically prohibited without written consent from LexisNexis.
+ READ MORE - READ LESS

The articles on our website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice. The views and opinions expressed in this article are those of the author(s) and do not necessarily reflect the views or official position of Robins Kaplan LLP.

Disclaimer

Related Publications

November 2020
Explaining the Almost Unexplainable
David Prange, Benjamen Linden, Vivek Biswas - Intellectual Property Magazine
November 9, 2020
Hatch-Waxman Venue Is Further Narrowed
Jeffrey Alan Hovden, Haroon Mian
Fall 2020
ANDA Approvals
GENERICally Speaking Fall 2020
Fall 2020
ANDA Litigation Settlements
GENERICally Speaking Fall 2020
Fall 2020
Generic Launches
GENERICally Speaking Fall 2020
Back to Top